evaluate novo nordisk on glp-1 agonists Real-World Evaluation of Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes | Diabetes Therapy GLP-1 receptor agonists and next-generation

Description

BMI Reduction: Adolescents treated with semaglutide achieved a mean BMI reduction of 16.1%, compared with a 0.6% reduction in the placebo group

Lundgren JR, Janus C, Jensen SB, Juhl CR, Olsen LM, Christensen RM, et al

While these drugs were not initially approved for weight management, a small proportion of patients were using them to support weight loss, with doctors prescribing these off-label (off-label prescribing is where a drug is prescribed for a reason other than the one it is licensed for) in these cases, GLP-1RAs were given to people without diabetes but with a high body mass index (BMI)

fed female APOE*3-Leiden.CETP mice cholesterol-containing western-type diet for 5 weeks to induce atherosclerosis and then treated them with exendin-4 for the next 4 weeks ( in vivo

The administration of the triple agonist resulted in the improvement of steatohepatitis in a dose-dependent fashion, with some female mice showing a complete resolution